多靶点粪便DNA结直肠癌筛查项目十年纵向数据
该研究回顾性分析了多站点医疗系统内148,624次多靶点粪便DNA(mt-sDNA)检测,阳性率13.6%,65.1%的阳性者在12个月内完成结肠镜检查,阳性后进展期腺瘤诊断率30.7%、腺癌1.3%;但阴性后3年内仅35.3%重复mt-sDNA检测,提示筛查流程存在关键缺口。
要点
- mt-sDNA阳性后结肠镜优质检查中进展期腺瘤诊断率达30.7%,腺癌1.3%。
- 仅65.1%的阳性者在12个月内完成结肠镜,中位等待82天。
- 阴性后3年内仅35.3%重复mt-sDNA检测,依从性不足。
核心结论
- 十年mt-sDNA筛查项目结肠镜质量高,但阳性后随访和阴性后重复检测存在显著缺口。
研究设计与样本
- 回顾性队列研究,纳入2014年9月至2025年7月多站点医疗系统内148,624次mt-sDNA检测(110,410人),利用大语言模型管道从自由文本报告中提取结肠镜、病理和质量终点。
主要发现
- 总体阳性率13.6%,19,506例阳性者中65.1%在12个月内完成结肠镜,中位时间82天。
- 阳性后高质量结肠镜中进展期腺瘤诊断率30.7%,腺癌1.3%。
- 阴性mt-sDNA后3年内接受结肠镜者中,45.2%发现腺瘤/锯齿状病变,9.3%为进展期腺瘤,0.5%为结肠癌。
- 阳性后腺瘤检出率超过50%,高于专业学会质量基准,且随时间提升;阳性后结肠镜间隔超过6个月与进展期腺瘤风险升高相关(趋势P=0.001)。
- 首次阴性mt-sDNA后3年内仅35.3%再次接受mt-sDNA筛查。
临床怎么用
- 应加强阳性mt-sDNA患者的结肠镜随访管理,缩短等待时间至6个月内。
- 需建立系统提醒机制,提高阴性后按计划重复mt-sDNA检测的依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Multitarget stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. METHODS: We assembled a retrospective cohort of mt-sDNA tests (September 2014-July 2025) within a multisite health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality end points from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma [AA], sessile serrated lesion, and negative examinations) were calculated among high-quality examinations; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate used all screening examinations. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. RESULTS: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: AA diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had AA and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher AA (trend P = 0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. DISCUSSION: Over a decade, mt-sDNA screening achieved high colonoscopy quality but revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
引用
- Garg SK, Hintz CF, Kolarik HJ, et al. Longitudinal Data From a Large, Multitarget Stool DNA Colorectal Cancer Screening Program. Am J Gastroenterol. 2026. PMID: 42690929. doi:10.14309/ajg.0000000000004196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。